Sign in
CERS Stock Price, Chart, Stats & News
Cerus Corporation
Save
Cerus Corporation (CERS) does not currently pay a dividend.
528.00M
Market cap
–
Current P/E
–
Forward P/E
CERS chart
Fundamentals
Gross margin | 54.47% |
Operating margin | -4.21% |
Pretax margin | -7.41% |
Net margin | -7.58% |
Effective tax rate | -2.32% |
ROA | -7.04% |
ROE | -26.42% |
D/E | 1.51x |
Interest coverage ratio | -1.04x |
CERS valuation
P/E | – |
P/S | 1.66x |
P/B | 5.28x |
P/CF | 70.14x |
P/FCF | 308.72x |
P/OCF | 70.14x |
PEG | -8.24x |
EV multiple | -35.05x |
About
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.
Similar securities
Based on sector and market capitalization
Report issue